Treatment of atherosclerotic renovascular disease
Contribuinte(s) |
Universidade Estadual Paulista (UNESP) |
---|---|
Data(s) |
27/05/2014
27/05/2014
01/05/2008
|
Resumo |
Treatment of atherosclerotic renovascular disease is controversial and revascularization is not a beneficial approach to all patients. Conditions as progressive deterioration of renal function, refractory hypertension or accelerated cardiovascular disease, especially recurrent pulmonary edema, could profit from renal angioplasty with stent placement. Surgical revascularization is a good option for patients who will need concomitant surgical corrections of abdominal aortic lesions. Treatment of all other patients must be individualized. Medical therapy is indicated for all patients with atherosclerotic renovascular disease. Observational studies pointed out to the beneficial effect of controlling blood pressure (<130/80 mm Hg), glucose and lipids profile, lifestyle modifications, specific use of platelet antiaggregant therapy, Angiotensin Conversion Enzyme Inhibitors (ACEI) and statins. All others cardiovascular risk factors must be controlled. The evaluation and management of other systemic atherosclerotic vascular lesions is important, especially coronary, carotid and abdominal aortic. This paper presents a review of evidences to rationale the atherosclerotic renovascular disease treatment. © 2008 Bentham Science Publishers Ltd. |
Formato |
114-120 |
Identificador |
http://dx.doi.org/10.2174/157340208784245875 Current Hypertension Reviews, v. 4, n. 2, p. 114-120, 2008. 1573-4021 http://hdl.handle.net/11449/70404 10.2174/157340208784245875 2-s2.0-48249113788 |
Idioma(s) |
eng |
Relação |
Current Hypertension Reviews |
Direitos |
closedAccess |
Palavras-Chave | #Atherosclerosis #Medical therapy #Renal angioplasty #Renal artery stenosis #Renovascular #Treatment #angiotensin receptor antagonist #antithrombocytic agent #beta adrenergic receptor blocking agent #calcium channel blocking agent #cerivastatin #dipeptidyl carboxypeptidase inhibitor #glucose #hydroxymethylglutaryl coenzyme A reductase inhibitor #lipid #simvastatin #thiazide diuretic agent #vasodilator agent #abdominal aorta #acute kidney failure #angioplasty #aorta disease #atherosclerosis #blood pressure regulation #cardiovascular disease #cardiovascular risk #carotid artery disease #clinical feature #clinical protocol #clinical trial #coronary artery disease #deterioration #disease model #drug use #drug withdrawal #follow up #human #hypertension #kidney function #lifestyle modification #lung edema #metabolic regulation #nonhuman #pathogenesis #percutaneous transluminal angioplasty #priority journal #recurrent disease #renal artery #renovascular disease #revascularization #review #stent #treatment indication |
Tipo |
info:eu-repo/semantics/review |